Latest Videos

The Imperial College London are currently aiming towards single cell measurement in microfluidic chips in combination with hydrodynamic lab-on-chip cell separation techniques, as a potentially new channel for label-free tumour cell detection in biological liquids.

This talk will illustrate, with case studies, how appropriate and timely use of imaging biomarkers can significantly reduce the risk, cost and time of drug development.

The ability to rapidly determine if a patient has an infectious disease and what type of treatment the infection will respond to, would significantly reduce the treatment decision time, shorten the impact of symptoms, and minimize transfer to others.

The High Throughput Biomedicine unit at FIMM Technology Centre provides a wide range of biomedical high throughput assays.

This presentation will outline key issues in oncology biomarker testing and describe findings from a study of practices used by National Cancer Institute (NCI) designated cancer centers, the leading U.S. oncology institutions, for testing key biomarkers in three solid tumors - breast, gastroesophageal and non-small cell lung cancers.

Katja Arndt, University of Potsdam, speaking at Discovery Chemistry Congress 2015.

A lab-on-a-chip system called the "Fraunhofer ivD-platform" has been established which opens up the possibility for an on-site analysis at low costs.

Imaging has been at the heart of Medicine for many decades. However, its influence is changing as the need increases not only for diagnosis of disease, but also for quantification of disease extent, identification of suitable candidates for treatment and for testing of both treatment response or assessment of potential side effects for new treatments.

This talk presents the discovery and optimization of potent and selective MPS1 inhibitors based on the 1H-pyrrolo[3,2-c]pyridine scaffold, guided by structure-based design and cellular characterization of MPS1 inhibition.

Metabolomics has been successfully applied to identify and validate biomarkers for congestive heart failure. Diagnosis and risk stratification of heart failure (HF) is challenging.